Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study

International Journal of Rheumatic Diseases

Volumn 20, Issue 8, 2017, Pages 960-970

  Stock, Thomas ^a   Fleishaker, Dona ^a   Wang, Xin ^a   Mukherjee, Arnab ^a   Mebus, Charles ^a  

^a PFIZER INC   (United States)

Author keywords

arthritis; glucocorticoids; prednisone; randomized controlled trial; rheumatoid

Indexed keywords

C REACTIVE PROTEIN; C TELOPEPTIDE OF TYPE II COLLAGEN; COLLAGEN TYPE 2; FOSDAGROCORAT; GLUCOCORTICOID RECEPTOR; GLUCOSE; HYDROCORTISONE; METHOTREXATE; OSTEOCALCIN; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID; ORGANOPHOSPHATE; PHENANTHRENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSESSMENT OF HUMANS; ASTHENIA; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOON FACE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VIRUS INFECTION; ADULT; AGED; AGONISTS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONVALESCENCE; DISABILITY; DRUG EFFECT; JOINT; METABOLISM; MIDDLE AGED; PARTIAL AGONISM; PATHOPHYSIOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; C-REACTIVE PROTEIN; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG PARTIAL AGONISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; ORGANOPHOSPHATES; PHENANTHRENES; PREDNISONE; RECEPTORS, GLUCOCORTICOID; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85016024157     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.13053     Document Type: Article

References (28)

1. McDonough AK, Curtis JR, Saag KG (2008) The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20, 131–7.
2. Morand EF (2007) Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 19, 302–7.
3. Spies CM, Bijlsma JW, Burmester GR, Buttgereit F (2010) Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 10, 302–7.
4. Caplan L, Wolfe F, Russell AS, Michaud K (2007) Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 34, 696–705.
5. Gaujoux-Viala C, Nam J, Ramiro S et al. (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73, 510–5.
6. Criswell LA, Saag KG, Sems KM et al. (2000) Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev CD001158.
7. Kirwan J, Power L (2007) Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol 19, 233–7.
8. Bijlsma JW (2012) Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology (Oxford) 51, iv9–13.
9. Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34, 593–8.
10. Brown ES, Chandler PA (2001) Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 3, 17–21.
11. Brown ES, Suppes T, Khan DA, Carmody TJ III (2002) Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 22, 55–61.
12. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E (1996) Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 271, E317–25.
13. Schäcke H, Rehwinkel H, Asadullah K (2005) Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr Opin Investig Drugs 6, 503–7.
14. Takahashi H, Razavi H, Thomson D (2008) Recent progress in the discovery of novel glucocorticoid receptor modulators. Curr Top Med Chem 8, 521–30.
15. Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V et al. (2012) Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. PLoS One 7, e35155.
16. Harcken C, Riether D, Kuzmich D et al. (2014) Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects. J Med Chem 57, 1583–98.
17. Hu X, Du S, Tunca C et al. (2011) The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation. Endocrinology 152, 3123–34.
18. Zutshi A, Long K, Melton M et al. (2010) From Mouse to Man: The Pre-clinical to Clinical Translation of a DAGR. Poster presented at the Keystone Symposia-New Paradigms in Cancer Therapeutics, Victoria, Canada, 23–28 March, 2010.
19. Stock T, Fleishaker D, Mukherjee A, Le V, Xu J, Mebus C (2010) Evaluation of safety, pharmacokinetics and pharmacodynamics of a dissociated agonist of the glucocorticoid receptor (DAGR) in healthy volunteers. Poster presented at the European League Against Rheumatism Annual Congress, Rome, Italy, 16–19 June, 2010.
20. Smolen JS, Landewé R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492–509.
21. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44–8.
22. Felson DT, Anderson JJ, Boers M et al. (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38, 727–35.
23. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41, 1564–70.
24. Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1, 20.
25. Ware JE Jr (2000) SF-36 health survey update. Spine (Phila Pa 1976), 25, 3130–9.
26. Obukowicz M (2010) Dissociated Agonist of the Glucocorticoid Receptor (DAGR): 60 Years in the Making (and of Waiting). Poster presented at the Keystone Symposia-New Paradigms in Cancer Therapeutics, Victoria, Canada, 23–28 March, 2010.
27. Dickson MC, Cai G, Rioja I et al. (2008) Steroid responsive pharmacodynamic markers: results from a randomised placebo controlled trial in rheumatoid arthritis patients treated with prednisolone. Poster presented at the American College of Rheumatology Annual Congress, San Francisco, California, October 24–29, 2008.
28. Gerlag DM, Haringman JJ, Smeets TJ et al. (2004) Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 50, 3783–91.